vorinostat has been researched along with Chronic Hepatitis B in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hsieh, YH | 1 |
| Su, IJ | 1 |
| Yen, CJ | 1 |
| Tsai, TF | 1 |
| Tsai, HW | 1 |
| Tsai, HN | 1 |
| Huang, YJ | 1 |
| Chen, YY | 1 |
| Ai, YL | 1 |
| Kao, LY | 1 |
| Hsieh, WC | 1 |
| Wu, HC | 1 |
| Huang, W | 1 |
1 other study available for vorinostat and Chronic Hepatitis B
| Article | Year |
|---|---|
Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Nucleus; Cell Pro | 2013 |